Aleglitazar

Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes[1].

Product Specifications

CAS Number

[475479-34-6]

Product Name Alternative

R1439; RO0728804

UNSPSC

12352005

Hazard Statement

H302, H312, H315, H319

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/aleglitazar.html

Concentration

10mM

Purity

99.74

Solubility

DMSO : ≥ 50 mg/mL

Smiles

CC1=C(CCOC2=CC=C(C[C@@H](C(O)=O)OC)C3=C2C=CS3)N=C(C4=CC=CC=C4)O1

Molecular Formula

C24H23NO5S

Molecular Weight

437.51

Precautions

H302, H312, H315, H319

References & Citations

[1]Bénardeau A, Benz J, Binggeli A, et al. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorg Med Chem Lett. 2009 May 1;19 (9) :2468-73.|[2]Yan Chen, et al. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. Diab Vasc Dis Res. 2017 Mar; 14 (2) : 152–162.|[3]Valérie Boujon, et al. Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice. J Mol Med (Berl) . 2019; 97 (8) : 1127-1138.